Clinical effects of E. coli strain Nissle 1917 in cases of irritable bowel syndrome

In a multicentric study, 41 patients were treated with ­Mutaflor over a period of four weeks.50 ­Mutaflor therapy produced an improvement of the irritable symptoms in a majority of the patients. In particular, meteorism and the pain symptoms associated with it could be improved and the quality of life thus ­increased.

  • 78 % of the patients rated the tolerance of ­Mutaflor therapy as “good” to “very good”.

Pain rating (intensity, duration and frequency) of patients in diaries50


Patients with irritable bowel syndrome who had suffered from infection or had been treated with anti­biotics before the onset of their disease benefited significantly from a ­Mutaflor therapy which had lasted for several weeks.29
Probiotics such as E. coli strain Nissle 1917 are expressly recommended as a ­therapy option in cases of irritable bowel syndrome by the Guideline of the German Society of Digestive and Metabolic ­Diseases (DGVS).51

29) Kruis W et al., A double-blind placebo-controlled trial to study therapeutic effects of probiotic Escherichia coli Nissle 1917 in subgroups of patients with irritable bowel syndrome. Int J Colorectal Dis 2012; 27(4): 467–474.

50) Keller J et al. Reizdarm-Patienten mit Meteorismus als dominantem Symptom profitieren von einer Therapie mit E. coli Nissle 1917 – Ergebnisse einer Pilotstudie. Z Gastroenterol 2010; 48: 955.

51) Layer P. S3-Leitlinie Reizdarmsyndrom: Definition, Pathophysiologie, Diagnostik und Therapie. Z Gastroenterol 2011; 49: 237–293.

Mutaflor international package insert to download
Mutaflor Suspension international package insert to download